- Home
- RPRX vs RNR Comparison
RPRX vs RNR Comparison
Compare RPRX & RNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- RNR
- Stock Information
- Founded
- RPRX 1996
- RNR 1993
- Country
- RPRX United States
- RNR Bermuda
- Employees
- RPRX N/A
- RNR N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- RNR Property-Casualty Insurers
- Sector
- RPRX Health Care
- RNR Finance
- Exchange
- RPRX Nasdaq
- RNR Nasdaq
- Market Cap
- RPRX 13.9B
- RNR 11.8B
- IPO Year
- RPRX 2020
- RNR 1995
- Fundamental
- Price
- RPRX $35.59
- RNR $236.00
- Analyst Decision
- RPRX Strong Buy
- RNR Buy
- Analyst Count
- RPRX 3
- RNR 11
- Target Price
- RPRX $48.33
- RNR $287.40
- AVG Volume (30 Days)
- RPRX 3.5M
- RNR 462.5K
- Earning Date
- RPRX 08-06-2025
- RNR 07-23-2025
- Dividend Yield
- RPRX 2.48%
- RNR 0.68%
- EPS Growth
- RPRX 37.60
- RNR N/A
- EPS
- RPRX 2.45
- RNR 31.81
- Revenue
- RPRX $2,263,845,000.00
- RNR $12,613,932,000.00
- Revenue This Year
- RPRX $29.35
- RNR N/A
- Revenue Next Year
- RPRX $7.58
- RNR $1.24
- P/E Ratio
- RPRX $14.47
- RNR $7.44
- Revenue Growth
- RPRX 1.13
- RNR 31.51
- 52 Week Low
- RPRX $24.05
- RNR $210.51
- 52 Week High
- RPRX $36.89
- RNR $300.00
- Technical
- Relative Strength Index (RSI)
- RPRX 52.61
- RNR 42.56
- Support Level
- RPRX $35.24
- RNR $235.94
- Resistance Level
- RPRX $36.89
- RNR $239.92
- Average True Range (ATR)
- RPRX 0.62
- RNR 4.03
- MACD
- RPRX -0.14
- RNR -0.27
- Stochastic Oscillator
- RPRX 22.16
- RNR 15.87
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.